Few companies in the FTSE 100 have built a reputation for steady compounding quite like Diploma. The specialist distributor of seals, controls and life sciences products rarely makes dramatic headlines, yet it has once again given the market a reason to pay attention. With its financial year drawing to a close at the end of September, attention is turning to how much of this year's momentum can be carried forward.
Diploma (LSE:DPLM), a FTSE 100 constituent, used its third-quarter trading update on 16 July 2026 to raise its full-year guidance. It pointed to faster organic growth, a higher Operating Margin and a sizeable new Acquisition in the United States. The upgrade has kept the group firmly on the radar of growth-focused investors ahead of full-year results in November.
A third quarter that beat the company's own expectations
The headline number was organic Revenue growth of 15% in the third quarter, a strong figure for a Business that sells essential but often unglamorous components to industrial, defence and healthcare customers. Management said the Controls division was the standout, with several of its businesses, including IS Group, Clarendon, Peerless and Windy City Wire, all delivering double-digit growth.
The picture elsewhere was more mixed but still constructive. Seals showed improving momentum, with North America performing well even though some international markets were described as patchy. Life Sciences was resilient despite tougher market conditions and a product refresh cycle. The overall message was that the group's broad portfolio continues to offset softness in any one area.
Inside the upgraded numbers
On a constant-currency basis, Diploma now expects organic revenue growth of about 14% for the financial year to 30 September 2026, up from the roughly 12% it had previously guided. It also lifted its operating margin expectation to around 26.5%, from about 25% before. Acquisitions are expected to add a further 6% to reported revenue growth.
Taken together, the company said these changes point to operating profit growth of around 42% at constant currency. According to the trading update, that represents an upgrade of about 7% to market consensus. Notably, margin improvement is doing much of the work, which suggests the group is extracting more value from each pound of sales rather than relying on Volume alone.
The quarter also saw the completion of the CDM acquisition on 25 June 2026. On the analyst call, management described it as a $170m deal for a business generating more than $80m of revenue, giving Diploma an interconnect platform in the US with positions in the defence market. Diploma said it had completed 15 acquisitions over the previous 12 months, which it described as a record.
Why the model keeps attracting a premium
Diploma's appeal rests on a simple but hard-to-copy formula. It buys small, well-run specialist businesses, lets them keep their entrepreneurial culture, and supports them with Capital and central expertise. Because its products are often a small part of a customer's total cost but critical to performance, the group has historically been able to hold pricing and margins through different parts of the cycle.
The latest update reinforced that story. Organic growth in the mid-teens is unusual for an industrial distributor, and a rising margin shows that growth is not being bought through discounting. Management was open about the one area where it is deliberately trading margin for volume, explaining on the call that it is moderating spot pricing at Peerless to drive growth while adding resources.
The CDM deal also fits a wider theme. Defence spending across Europe and North America has been rising, and exposure to that end market adds another resilient Demand stream to the portfolio. With a strong acquisition pipeline and what the company called significant Balance Sheet headroom, Diploma has room to keep adding bolt-on deals of this kind.
The risks behind a premium valuation
The flip side of consistent outperformance is that expectations are now high. Chief executive Johnny Thomson acknowledged as much on the call, saying: "This is not a normal year for us." He added that the group would not deliver the current rate of Earnings growth every year, a clear signal that 2027 comparisons will be tougher.
Acquisition-led growth carries its own risks. Integrating 15 businesses in a year stretches management attention, and a poorly judged deal or an overpayment could dent returns. Higher interest rates or tighter Credit conditions would also raise the cost of funding future purchases, while competition for attractive targets can push up prices.
There are external risks too. Industrial demand can weaken quickly if economic growth slows, and some of Diploma's businesses are sensitive to trade policy, tariffs and currency movements, given its significant North American exposure. Life Sciences has already faced softer conditions, and any broader slowdown in healthcare spending could weigh on that division. Finally, a premium valuation leaves less room for disappointment if growth cools from these elevated levels.
Key dates and catalysts ahead
The next major milestone is the full-year results, scheduled for 17 November 2026. Investors will be watching whether the group has delivered on its raised guidance of around 14% organic growth and a margin of about 26.5%, and how quickly CDM is contributing.
Just as important will be the first guidance for the 2027 financial year. Management has already hinted that growth will normalise, so the key questions are how far and how fast. Commentary on the acquisition pipeline, pricing at Peerless and the health of the Seals and Life Sciences divisions should also shape sentiment.
Beyond the results, any further bolt-on deals, particularly in defence or other structurally growing end markets, could add to the Investment case. Broader signals on industrial activity in the US and Europe will also matter, since they drive demand across much of the portfolio.
Conclusion
For Diploma (LSE:DPLM), the July upgrade showed a business firing on several cylinders at once, with double-digit organic growth, expanding margins and a steady flow of acquisitions. That combination explains why it continues to win over investors. However, management itself has flagged that this year's growth rate is exceptional, and the November results will show how smoothly the group can move to a more normal pace.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...